Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949148 | 0.83 | HCRTR1 (0.53) | HCRTR2HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL9949445 | 0.83 | HCRTR1 (0.75) | HCRTR2HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL9948895 | 0.82 | HCRTR2 (0.71) | HCRTR2HCRTR1 | |
| SCHEMBL9948782 | 0.82 | HCRTR1 (0.56) | HCRTR2HCRTR1 | |
| SCHEMBL2136349 | 0.82 | HCRTR2 (0.68) | HCRTR2HCRTR1 | |
| SCHEMBL9948715 | 0.81 | HCRTR1 (0.49) | HCRTR2HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL9948661 | 0.78 | HCRTR1 (0.50) | HCRTR2HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL9948899 | 0.78 | HCRTR1 (0.72) | HCRTR2HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL9948984 | 0.78 | HCRTR1 (0.72) | HCRTR2HCRTR1KDM4EALDH1A1HPGD | |
| SCHEMBL9948897 | 0.78 | HCRTR1 (0.52) | HCRTR2HCRTR1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | HCRTR2 607/4885HCRTR1 593/4885KDM4E 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.